Table 3. Baseline characteristics of patients included in the validation cohorts.
| EAP (N=115) | CD (N=72) | |
|---|---|---|
|
Age, years | ||
| Median, range | 63 (23–88) | 62 (21–82) |
|
Gender,
N
(%) | ||
| Female | 49 (43) | 28 (39) |
| Male | 66 (57) | 44 (41) |
|
Primary site,
N
(%) | ||
| Cutaneous | 85 (74) | 60 (83) |
| Mucosal | 14 (12) | 4 (6) |
| Ocular | 7 (6) | 6 (8) |
| Unknown | 9 (8) | 2 (3) |
|
Serum LDH,
N
(%) | ||
| <ULN | 51 (46) | 28 (39) |
| ⩾ ULN | 61 (54) | 43 (61) |
| NA | 3 | 1 |
|
ECOG PS,
N
(%) | ||
| 0–1 | 107 (93) | 67 (93) |
| 2 | 8 (7) | 5 (7) |
|
Previous lines of systemic therapy | ||
| 1 | 65 (57) | 61 (85) |
| ⩾2 | 50 (43) | 11 (15) |
|
Institution,
N
(%) | ||
| European Institute of Oncology | 38 (33) | 39 (54) |
| Istituto Dermopatico dell'Immacolata | 47 (41) | 33 (46) |
| University Hospital of Siena | 30 (26) | 0 |
Abbreviations: CD=commercial drug; EAP=Expanded Access Programme; ECOG PS=European Cooperative Oncology Group performance status; LDH=lactate dehydrogenase; NA=not available; ULN=upper limit of normal.